In a prospective randomized study, we examined whether a novel method of ovarian stimulation, the bromocriptine-rebound method, improves in vitro fertilization (IVF) outcomes compared with the conventional long protocol using GnRH agonist and human menopausal gonadotropin (hMG). Ovulatory women with previous failed IVF-embryo transfer using the long protocol were prospectively assigned to either the bromocriptine-rebound method (group 1, 82 cycles) or the long protocol (group 2, 80 cycles). The bromocriptinerebound method was the same as the long protocol, except that bromocriptine was administered daily from day 4 of the preceding cycle until 7 days before hMG stimulation. The numbers of follicles, fertilized oocytes, and embryos with superior morphology were higher in group 1 than in group 2. The rates of clinical pregnancy and live birth delivery per cycle were significantly higher in group 1 (38% and 33%, respectively) than in group 2 (21% and 19%, respectively). The mean concentration of serum PRL during hMG administration was significantly higher in group 1 than group 2. A significant correlation between the number of superior embryos and PRL concentrations was observed in group 1, but not in group 2.
Next, we performed a retrospective study to investigate how the bromocriptine-rebound method exerts its beneficial effects. In the initial IVF with the long protocol, the mean concentration of serum PRL during hMG administration and the expression of PRL receptor (PRLr) messenger ribonucleic acid (mRNA) in granulosa cells were significantly higher in nonpregnant patients than in pregnant ones. When IVF was repeated with the bromocriptine-rebound method in the nonpregnant patients, the expression of PRLr mRNA decreased significantly. In conclusion, the bromocriptine-rebound method enhances embryonic development and the rate of live birth delivery in patients with previous failed IVF using the long protocol. We hypothesize that in the nonpregnant patients using the long protocol, the serum PRL concentration and PRLr mRNA expression are increased to compensate for poor postreceptor responsiveness of granulosa cells to PRL during oocyte maturation. The bromocriptine-rebound method may improve oocyte maturation in such patients by restoring postreceptor responsiveness of granulosa cells to PRL during the hypoprolactinemic period and increasing the PRL concentration by a rebound phenomenon after discontinuation of bromocriptine. (J Clin Endocrinol Metab 82: 3603-3611, 1997) O NE OF THE most crucial factors in achieving pregnancy in humans by in vitro fertilization (IVF) is the ability to obtain fully matured oocytes. For this purpose, various methods of ovarian stimulation have been developed, using clomiphene citrate (1), human menopausal gonadotropin (hMG) (2) , and GnRH agonists (GnRH-a) (3) . Consequently, an adequate pregnancy rate is achieved for many patients, although there are still patients who do not respond well to conventional methods. The standard methods of ovarian stimulation stimulate follicular development almost exclusively by increasing gonadotropin concentrations through modulation of endogenous gonadotropin secretion and/or administration of exogenous gonadotropins. In natural menstrual cycles, however, normal growth and maturation of oocytes are accomplished by the orchestrated action of pituitary gonadotropins as primary endocrine regulators as well as many other endocrine/paracrine/autocrine factors, such as steroids, growth factors, inhibin/ activin/follistatin, and cytokines (4) . A GH/insulin-like growth factor system is viewed as one such regulatory factor (4); adjuvant GH therapy with gonadotropin stimulation has recently been attempted, but has shown only minor beneficial effects (5) .
PRL is also known to play a significant role in regulating ovarian functions, including folliculogenesis, steroidogenesis, ovulation, and corpus luteum function (6) . The PRL and GH receptors as well as the hormones themselves are homologous, forming a protein family encoded by related genes (7) . Because several clinical and animal investigations support a stimulatory role for PRL in growth and maturation of oocytes (8 -11) , we have devised a new method of ovarian stimulation, the bromocriptine-rebound method, in which the endogenous PRL concentration during gonadotropin stimulation is increased by a rebound phenomenon after discontinuation of bromocriptine administration (12) . Our clinical trial (12) showed that the bromocriptine-rebound method significantly improves embryonic development and the pregnancy rate compared with the conventional long protocol using GnRH-a and hMG, currently the most widely used method in IVF programs. In this report, we first conducted a prospective randomized study (study I) to confirm that the bromocriptine-rebound method improves IVF outcomes compared with the conventional long protocol. Next, retrospective analyses (study II) were performed to determine how the bromocriptine-rebound method exerts its beneficial effects and which patients should respond to this method.
Materials and Methods

Patients and study design
Endocrinologically normal ovulatory women under 40 yr of age with at least one unsuccessful IVF attempt using the conventional long protocol of the GnRH-a and hMG regimen, were selected for study I. Normal concentrations of serum PRL were confirmed at least twice at intervals more than 3 weeks apart. Patients whose partners had abnormal semen analyses according to the WHO criteria (13) were excluded. Patients were prospectively assigned at random to receive either the bromocriptine-rebound method or the long protocol of the GnRH-a and hMG regimen for ovarian stimulation. Randomization was performed as follows: 200 sealed envelopes indicating either method on inside cards (100 for each method) were shuffled, and 1 envelope was drawn on day 4 of the follicular phase in the preceding cycle. Consequently, 82 and 80 cycles of IVF in 68 and 70 patients were performed using the bromocriptine-rebound method and long protocol, respectively. The IVF outcomes and hormonal data were compared between the 2 groups to examine clinical efficacy and endocrinological effects of the bromocriptinerebound method. No significant difference was observed between the bromocriptine-rebound method and long protocol groups with respect to mean age (mean Ϯ sem, 34.1 Ϯ 0.3 and 34.1 Ϯ 0.4 yr, respectively), the number of previous failed IVF attempts (1.6 Ϯ 0.1 and 1.4 Ϯ 0.1, respectively), and the distribution of the causes of infertility, which consisted of tubal infertility (71% and 70%, respectively), endometriosis (6.1% and 8.8%, respectively), and unexplained infertility (23% and 21%, respectively).
In study II we retrospectively analyzed data from a total of 149 cycles of initial IVF attempts using the long protocol of the GnRH-a and hMG regimen for ovarian stimulation. The study included only endocrinologically normal ovulatory women younger than 40 yr of age, whose partners had normal semen analyses. The mean age was 33.0 Ϯ 0.3 yr, and the causes of infertility consisted of tubal infertility, endometriosis, and unexplained infertility (71.8%, 9.4%, and 18.8%, respectively). First, hormonal data were compared between pregnant (79 cycles) and nonpregnant (70 cycles) initial IVF attempts. Next, serum PRL concentrations were compared among 4 groups as follows; group A, in which initial IVF with the long protocol resulted in an ongoing pregnancy (47 cycles); group B, in which initial IVF with the long protocol failed, but repeated IVF with the long protocol resulted in an ongoing pregnancy (4 cycles); group C, in which initial IVF with the long protocol failed, but repeated IVF with the bromocriptine-rebound method resulted in an ongoing pregnancy (15 cycles); and group D, in which initial IVF with the long protocol and repeated IVF with the long protocol and/or the bromocriptine-rebound method did not result in an ongoing pregnancy (28 cycles). The remaining 55 cycles were excluded from this analysis because they did not repeat IVF. Finally, some patients were selected at random from the patient population in studies I and II, and the TRH test and measurements of the expression of PRL receptor (PRLr) messenger ribonucleic acid (mRNA) in granulosa cells were performed. The results were compared among 3 groups of patients, consisting of pregnant and nonpregnant initial IVF with the long protocol and repeated IVF with the bromocriptine-rebound method (the TRH test in 7, 9, and 7 patients, respectively, and PRLr mRNA measurements in 3, 7, and 6 patients, respectively).
Both studies I and II were approved by the Kyorin University ethical committee.
Ovarian stimulation regimens
In the bromocriptine-rebound method (Fig. 1) , bromocriptine (Parlodel, Sandoz, Tokyo, Japan) was administered orally at a dose of 1.25 mg/day from days 4 -6 of the follicular phase in the preceding cycle, and thereafter at 2.5 mg/day. The administration of bromocriptine was discontinued 7 days before the beginning of hMG administration. Nasal administration of buserelin acetate (Suprecur, Hoechst, Tokyo, Japan) (900 g/day) was started on day 4 of the luteal phase in the preceding cycle and continued at the same dose until administration of hCG. Ovarian suppression was confirmed by a serum 17␤-estradiol concentration of less than 20 pg/mL [conversion factor to Systeme International (SI) unit, 3 .671] and the absence of follicle greater than 12 mm in diameter on transvaginal ultrasonography. Daily administration of three ampules of hMG (Humegon, Organon, Tokyo, Japan; 75 IU LH plus 75 IU FSH in each ampule) was begun between days 3 and 10 of the follicular phase in the IVF cycle. Serum concentrations of 17␤-estradiol, PRL, LH, and GH were measured every morning until the day of oocyte retrieval. When the serum 17␤-estradiol concentration exceeded 200 pg/mL (conversion factor to SI unit, 3.671), the dosage of hMG was reduced to two ampules per day. hCG (10,000 IU) was administered when one or more follicles were greater than 17 mm in diameter and the serum 17␤-estradiol concentration was above 400 pg/mL (conversion factor to SI unit, 3.671). Oocytes were collected transvaginally 36 h after hCG administration. The long protocol of the GnRH-a and hMG regimen ( Fig.  1 ) was similar to the bromocriptine-rebound method, except that bromocriptine was not administered.
IVF-embryo transfer (ET) procedures
Oocyte maturity at retrieval was assessed according to the morphology of the cumulus mass and corona radiata (14) . Semen was washed twice by centrifugation, and motile spermatozoa were collected by a swim-up technique. Oocytes were inseminated 2-6 h after their retrieval at a concentration of 100,000 progressively motile spermatozoa/mL. Human tubal fluid medium (no. 9962, Irvine Scientific, Santa Ana, CA) with 10% patient serum was used for IVF and embryo culture as previously reported (15) . Oocytes were considered to be fertilized when two pronuclei were observed 16 -18 h after insemination. Embryos were transferred 38 -48 h after insemination. Morphologically superior embryos were defined as grades 1 and 2 according to Veeck's criteria (16) . A 25-mg dose of progesterone was administered daily throughout the luteal phase. Clinical pregnancy was defined as the presence of a gestational sac on an ultrasonogram, and an ongoing pregnancy was a normal gestation beyond 16 weeks, including already delivered pregnancies.
Hormone determinations and TRH test
The serum concentrations of 17␤-estradiol, PRL, and GH were measured by RIA [estradiol kit, Diagnostic Products Corp. (Los Angeles, CA); Spack-S PRL, Daiichi Radioisotope (Tokyo, Japan); and GH kit, Daiichi Radioisotope]. The sensitivities of the 17␤-estradiol, PRL, and GH assays were 10 pg/mL, 1.0 ng/mL, and 0.01 ng/mL (conversion factors to SI units: 17␤-estradiol, 3.671; PRL, 32.5; GH, 2.000), respectively. The intra-and interassay coefficients of variation were 5.6% and 6.8% for 17␤-estradiol, 6.3% and 6.9% for PRL, and 5.3% and 6.9% for GH, respectively. The serum concentrations of LH and hCG were measured by enzyme immunoassay (IMx LH and IMx hCG, Dainabot, Tokyo, Japan). The sensitivities of the LH and hCG assays were 0.5 and 0.7 IU/L, respectively. The intra-and interassay coefficients of variation were 4.7% and 4.7% for LH and 4.2% and 4.7% for hCG, respectively.
The TRH test was performed 3 days before the beginning of hMG administration. Blood samples for PRL measurements were drawn just before and 15, 30, 60, and 120 min after the iv administration of 500 g TRH (Hirtonin, Takeda, Tokyo, Japan). The maximal PRL levels and relative increment, i.e. maximal PRL/basal PRL, were analyzed.
Granulosa cell preparation
Granulosa cells were harvested from follicles larger than 16 mm in diameter at oocyte retrieval. Follicular aspirates were centrifuged at 1500 rpm for 10 min, and the supernatants were decanted. Cells were resuspended in Dulbecco's phosphate-buffered saline (PBS; 14287-080, Life Technologies, Tokyo, Japan) and centrifuged at 1500 rpm for 10 min. Cells were resuspended in 4 mL PBS, layered on 4 mL 50% Percoll, and centrifuged at 1500 rpm for 30 min to pellet red blood cells. A purified granulosa cell preparation was aspirated from the interface and washed three times in PBS by centrifugation at 1500 rpm for 10 min. The cell pellet was plunged into liquid nitrogen and stored until later RNA analysis.
Quantitative RNA analysis
In humans, two different PRLr isoforms have been identified (17) . For detection of human PRLr mRNA by reverse transcription-PCR (RT-PCR), two oligonucleotide primers (forward primer, 5Ј-ACTATGAG-GACTTGCTGGTGGAGTATTT-3Ј; reverse primer, 5Ј-CACTTGCTT-GATGTTGCAAGTGAAGTT-3Ј) were used as described previously (17) .
Total RNA was isolated from granulosa cells using acid guanidium thiocyanate-phenol-chloroform (18) , then digested with ribonucleasefree pancreatic deoxyribonuclease I (Takara Shuzo Co., Kyoto, Japan) at 37 C for 10 min. Subsequently, total RNA was extracted with phenolchloroform, precipitated, and resuspended. One microgram of total RNA was reverse transcribed at 37 C using random 9-mer (Takara Shuzo Co.) and avian myeloblastosis virus reverse transcriptase XL (Takara Shuzo Co.) in a 40-L reaction solution supplemented with 40 U ribonuclease inhibitor (Takara Shuzo Co.). One microliter of RT products was amplified by PCR. The reaction was carried out in Takara Ex Taq buffer (Takara Shuzo Co.), 200 mol/L deoxy-NTPs, 50 mol/L forward and reverse primers, and 1.25 U Takara Ex Taq polymerase (Takara Shuzo Co.) in a total volume of 50 L overlaid with light mineral oil. The amplification profile was 1 min each of denaturation at 94 C, annealing at 55 C, and extension at 72 C after initial denaturation at 94 C for 5 min.
The procedures for quantitative PCR were essentially based on those reported by Martini et al. (19) with some modifications. In preliminary experiments, we tested various amplification cycles using 1 g total RNA from human granulosa cell samples to determine appropriate conditions for quantitative PCR (data not shown). The exponential phase of the reaction lasted up to 36 cycles, followed by a plateau phase. Thus, PCR was carried out for 33 cycles throughout this study. For quantitative analysis of PCR products, 10 L PCR products were separated on 2% agarose gels and stained with ethidium bromide. The pixel count of stained DNA bands was quantified on a BioImage analyzer (Millipore Corp., Ann Arbor, MI).
Statistical analysis
Data were analyzed using the 2 square test, Fisher's exact test, ANOVA, Fisher's protected least significant difference (PLSD) test, Student's t test, or Pearson analysis as appropriate. P Ͻ 0.05 was considered significant. Results are presented as the mean Ϯ sem unless otherwise stated.
Results
Study I
Significantly more follicles developed with the bromocriptine-rebound method than with the long protocol ( Table 1) . The serum concentration of 17␤-estradiol on the day of hCG administration was significantly higher with the bromocriptine-rebound method than with the long protocol. The numbers of fertilized oocytes and cleaved embryos were significantly higher with the bromocriptine-rebound method than with the long protocol ( Table 2 ). Significantly more embryos had superior morphology consistent with grades 1 and 2 of Veeck's classification (14) with the bromocriptine-rebound method than with the long protocol. Consequently, the rates of clinical pregnancy and live birth delivery were significantly higher with the bromocriptine-rebound method than with the long protocol. There were no significant differences between bromocriptine-rebound method and long protocol groups in the quality of semen used for IVF: volume, 3. The concentration of PRL decreased gradually from the luteal phase of the preceding cycle until day Ϫ4 (P Ͻ 0.0001, by paired t test) and then increased rapidly until day ϩ2 (P Ͻ 0.0001, by paired t test) in the long protocol (Fig. 2) . In the bromocriptine-rebound method, the concentration of PRL significantly decreased with bromocriptine treatment, but increased significantly beyond the pretreatment value after discontinuation of bromocriptine. The concentration of PRL then gradually decreased between the initial day of hMG administration and day Ϫ5 (P Ͻ 0.0001, by paired t test) and increased rapidly between days Ϫ3 and ϩ2 (P Ͻ 0.0001, by paired t test). All PRL values from 4 days after the discontinuation of bromocriptine until day ϩ2 were significantly elevated compared with that before bromocriptine treatment. The concentration of PRL on any day from the initial day of hMG administration until day 0 was significantly higher in the bromocriptine-rebound method than in the long protocol. The mean concentration of PRL during administration of hMG (from the initial day of hMG until day 0) was significantly higher in the bromocriptine-rebound method than in the long protocol (13.0 Ϯ 1.0 and 8.4 Ϯ 0.5, respectively; P Ͻ 0.0001, by unpaired t test).
With the bromocriptine-rebound method and the long protocol, the serum concentration of GH decreased from the luteal phase of the preceding cycle until the initial day of hMG administration (P Ͻ 0.0001, by paired t test), increased from days Ϫ6 and Ϫ4, respectively, until day 0 (P Ͻ 0.0001, by paired t test), and dropped rapidly on day ϩ1 (P Ͻ 0.0001, by paired t test) (Fig. 2) . Between the bromocriptine-rebound method and long protocol groups, however, there was no significant difference in the GH concentration on any day of observation (P Ͼ 0.05, by unpaired t test). The concentrations of 17␤-estradiol in the luteal phase of the preceding cycle as well as on any day from day Ϫ6 until day 0 were significantly higher with the bromocriptine-rebound method than with the long protocol (Fig. 2) . The serum concentration of LH was not significantly different between the two methods on any day of observation (P Ͼ 0.05, by unpaired t test; data not presented).
A significant correlation between the serum concentration of PRL and the number of morphologically superior embryos was observed the day before, the day of, and the day after hCG administration with the bromocriptine-rebound method (r ϭ 0.27, 0.24, and 0.36, respectively; P Ͻ 0.05, by Pearson analysis), but not on any day of PRL measurement with the long protocol (Fig. 3) .
Study II
The serum concentrations of PRL, GH, and 17␤-estradiol were compared retrospectively between pregnant and nonpregnant initial IVF attempts using the long protocol (Table  3 ). The mean concentration of PRL during hMG administration was significantly higher in nonpregnant cycles than in pregnant ones, whereas there was no significant difference in the mean concentrations of GH during hMG administration.
The serum concentrations of PRL in initial IVF attempts with the long protocol were compared among four groups, into which patients were classified according to which of methods, bromocriptine-rebound method or long protocol, resulted in an ongoing pregnancy in the initial and repeated IVF attempts. The PRL concentration 3 days after the onset of menstruation in the IVF cycle was significantly higher in group C, in which the bromocriptine-rebound method was effective, than in groups A and B, in which the long protocol was effective (Fig. 4) .
There were no significant differences among three groups of pregnant and nonpregnant initial IVF with the long protocol and repeated IVF with the bromocriptine-rebound method in the maximal PRL level (39.7 Ϯ 4.4, 43.7 Ϯ 4.0, and 47.1 Ϯ 5.5 ng/mL, respectively) and the relative increment This study used oligonucleotide primers matching the sequences of the intracytoplasmic domains of both the long and intermediate isoforms of human PRLr. The expression of long PRLr mRNA was detected in human granulosa cells, whereas the intermediate PRLr mRNA transcript was not (Fig. 5) . The level of expression of long PRLr mRNA differed among patients (Fig. 5) , and further quantitative analysis was performed (Fig. 6 ). In the initial IVF attempts with the long protocol, the expression of long PRLr mRNA was significantly higher in nonpregnant patients than in pregnant ones. When IVF was repeated with the bromocriptine-rebound method in nonpregnant patients with the long protocol, expression of long PRLr mRNA decreased significantly. 
FIG. 2. Serum concentrations of PRL (top panel), GH (middle panel)
, and 17␤-estradiol (bottom panel) during ovarian stimulation with the bromocriptine-rebound method (F-F; 82 cycles) and the long protocol (x----x; 80 cycles). In the bromocriptine-rebound method, bromocriptine was administered from the follicular phase in the preceding cycle (Pre F) until 7 days before the beginning of hMG treatment (Last Bro). In both methods, buserelin was administered from the luteal phase in the preceding cycle (Pre L) until the day of hCG (0 d). *, P Ͻ 0.05 between two methods (by unpaired t test); #, P Ͻ 0.0001 vs. any other PRL data in bromocriptine-rebound method (by paired t test); §, P Ͻ 0.0001 vs. PRL value on Last Bro in bromocriptine-rebound method (by paired t test). To convert values for 17␤-estradiol to picomoles per L, multiply by 3.671.
Discussion
This study demonstrated that in patients who previously failed in IVF-ET using the long protocol, the bromocriptinerebound method improves folliculogenesis and subsequent embryonic development, resulting in a significant increase in the rate of live birth delivery. Nonpregnant patients with the long protocol are characterized by increased serum PRL concentrations and enhanced PRLr mRNA expression in granulosa cells. The bromocriptine-rebound method increases the serum PRL concentrations further and decreases the expression of PRLr mRNA in granulosa cells, and these changes appear to be associated with the beneficial effects of the rebound method.
A midcycle increase in serum PRL concentrations and PRL receptors in granulosa cells has been demonstrated in humans (6), and abnormal follicular development was observed in a woman with isolated PRL deficiency (20) . These observations suggest that PRL plays a physiological role in human folliculogenesis. In human IVF, high concentrations of PRL in follicular fluid are associated with maturation of the oocyte-cumulus complex, successful fertilization, and pregnancy (8) . Hypoprolactinemia, induced with continuous administration of bromocriptine, is associated with lower rates of fertilization (10, 11) and embryonic cleavage (11) . Direct supplementation of PRL into the medium for in vitro maturation of rabbit oocytes enhances subsequent embryonic development in a dose-dependent manner (9) . Therefore, PRL appears to play a stimulatory role in the growth and maturation of oocytes, promoting fertilization and embryonic development.
Oocyte maturation consists of nuclear, cytoplasmic, and membranous changes; the completion of these maturational changes confers upon the oocyte the capacity for normal fertilization and embryonic development (21) . Nuclear maturation can be assessed to some extent by the observation of a first polar body, whereas no reliable, noninvasive markers e Data on the day of hCG administration. of cytoplasmic and membrane maturation have been established to date, other than observation of fertilization and embryonic development. In our previous study (12) , the number of oocytes with a first polar body was similar between the bromocriptine-rebound method and the long protocol. It is often observed in humans as well as in other mammals that inadequate maturation of cytoplasm and membrane leads to fertilization failure and impaired embryo viability, even with completion of nuclear maturation (21) . The bromocriptine-rebound method probably improves cytoplasmic and membrane maturation, resulting in an increase in embryo viability. In this study, assessment of oocyte maturity according to the morphology of the cumulus mass and corona radiata does not appear to be sensitive enough to detect an improvement in oocyte maturation due to the bromocriptine-rebound method.
To explain the results of the present study, we propose the hypothesis illustrated in Fig. 7 . Patients with poor IVF outcomes using the long protocol may have low responsiveness of granulosa cells to PRL, possibly in the postreceptor pathway, causing compensatory increases in the levels of serum PRL, PRLr mRNA, and PRLr. It is likely, however, that the compensation is inadequate, so that oocyte maturation is impaired. In such patients, the bromocriptine-rebound method probably improves oocyte maturation by restoring postreceptor responsiveness of granulosa cells to PRL during the hypoprolactinemic period and increasing the serum PRL concentration by a rebound phenomenon after discontinuation of bromocriptine. A decrease in the expression of PRLr mRNA appears to reflect the recovery of postreceptor responsiveness to PRL. Testing this hypothesis clearly requires a direct analysis of PRLr levels. In preliminary experiments, however, we have failed to detect the amount of PRLr in human granulosa cells by means of autoradiography using [ 125 I]PRL as well as by flow cytofluorometry and immunocytochemistry using a monoclonal antirat PRLr antibody, U5, which has been shown to cross-react with human PRLr (22) . It is not clear why we could not detect PRLr, but there are some possible reasons other than methodological ones. A single class of PRLr with high binding affinity has been demonstrated by Scatchard analysis in human granulosa cells, but the number of binding sites is limited (23) . [
125 I]PRL binding to granulosa is markedly reduced at the time of and after the gonadotropin surge in hamsters (24) . Thus, the timing of granulosa cell retrieval in the present study may not have been appropriate for PRLr measurements because it was at the nadir of PRLr expression. Because changes in PRLr mRNA expression correspond roughly to those of PRLr (25) , and RT-PCR quantitation of mRNA is much more sensitive than methods to measure receptors, we analyzed PRLr mRNA expression in this study.
Long, intermediate, and short isoforms of PRLr have been identified in the rat, which differ in the lengths of their intracytoplasmic domains (7) . In humans, originally only a long PRLr isoform was identified (7), but recently an intermediate PRLr isoform was demonstrated in human breast carcinoma and lymphocytes (17) . In this study, however, long PRLr mRNA was detected in human granulosa cells, whereas the intermediate PRLr mRNA was not. This result agrees with the observation that in rat granulosa cells, the expression of long PRLr mRNA is 6-to 10-fold higher than that of short PRLr mRNA (26) .
The subjects in study I were not a special small subgroup such as poor IVF responders, but were a large population of patients whose previous IVF attempts using the long protocol had not achieved a viable pregnancy. Thus, PRL hyporesponders may be common and have not been identified simply because of the lack of a method to detect this disorder. However, it is more likely that PRL hyporesponsiveness in these patients is latent, i.e. compensated, in natural menstrual cycles, and that some factors in ovarian stimulation aggravate this condition to make it overt. Estrogens have been shown to stimulate PRL synthesis, storage, and secretion at the pituitary level (27) as well as to induce PRL receptors on effector cells (6, 7, 27) . It has been shown that PRL concentrations increase proportionally with the preovulatory increase in the LH pulse frequency before a significant increase in estradiol secretion (6) . This suggests a stimulatory mechanism affecting PRL secretion that is more directly related to LH release (6, 27) . Therefore, it is conceivable that hypogonadotropic hypogonadism by pituitary desensitization in the long protocol causes a decrease in PRL hormone and/or receptor levels, aggravating PRL hyporesponsiveness. However, the significance of overt PRL hyporesponsiveness as a cause of infertility in the general population remains to be seen.
This study has demonstrated excellent effectiveness of a new method of ovarian stimulation, the bromocriptinerebound method, in a prospective randomized trial in patients who previously failed in IVF-ET using the long protocol. The results are profoundly significant in offering a new approach to more optimal stimulation of folliculogenesis by coordinated modulation of gonadotropin and other endocrine hormones. In addition, the significance of follicular hyporesponsiveness to PRL as a new cause of infertility has been suggested and awaits further investigation. 
